English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Unfortunately, in the original publication of the article, a statement in the third paragraph of the discussion section has been published with an error. The statement in the discussion currently reads: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade 3 or lower (n = 28 in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without). The correct statement is: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade 3/4 (n = 28 in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without).

breast cancer research and treatment

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer